Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 2Sarcoma 1NET 1Gynecologic 1Endocrine 1Breast 1

Conditions

Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Gallbladder Neoplasms 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 14Doxorubicin 11Cyclophosphamide 11Biopsy 9Radiation 8atezolizumab 7Temozolomide 7X-Rays 6Vincristine 6Nivolumab 6Etoposide 6Bevacizumab 6liposomal doxorubicin 5fludarabine 5cabozantinib 5Sirolimus 5Radiotherapy 5Phantoms, Imaging 5Irinotecan 5Immunoglobulin G 5Ifosfamide 5Disulfides 5pembrolizumab 4Nuclear Medicine Department, Hospital 4temsirolimus 3palbociclib 3olaparib 3fludarabine phosphate 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
tivozanib × Sarcoma × 30 days × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡